Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remestemcel-L - Mesoblast

Drug Profile

Remestemcel-L - Mesoblast

Alternative Names: hMSC - Mesoblast; human mesenchymal stem cells - Mesoblast; JR-0301; JR-031; JR-031 HIE; JR-031EB; MSC-100; MSC-100-IV; OTI-010; OTI-020; OTI-021; Prochymal; Provacel; RYONCIL; Stromagen; TEMCELL HS Inj.

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Osiris Therapeutics
  • Developer Cleveland Clinic; JCR Pharmaceuticals; Mesoblast; Osaka University; Osiris Therapeutics
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Epidermolysis bullosa; Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease
  • Preregistration Epidermolysis bullosa
  • Phase III Back pain; Crohn's disease; Myocardial infarction; SARS-CoV-2 acute respiratory disease
  • Phase I/II Brain hypoxia-ischaemia; Ulcerative colitis
  • Discontinued Acute radiation syndrome; Chronic obstructive pulmonary disease; Type 1 diabetes mellitus

Most Recent Events

  • 26 Mar 2024 Mesoblast intends to resubmit BLA for Remestemcel-L in children with steroid-refractory acute Graft versus host disease during the next quarter
  • 26 Mar 2024 The US FDA informes Mesoblast the available clinical data from Phase III MSB-GVHD001 trial appears sufficient to support the proposed BLA submission for Remestemcel-L in children with steroid-refractory acute Graft versus host disease
  • 31 Jan 2024 Mesoblast anticipates a meeting with the US FDA for remestemcel-L in the first quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top